
-
Verstappen quells speculation by committing to Red Bull for 2026
-
Study reveals potato's secret tomato past
-
Squiban solos to Tour de France stage win, Le Court maintains lead
-
Max Verstappen confirms he is staying at Red Bull next year
-
Mitchell keeps New Zealand on top against Zimbabwe
-
Vasseur signs new contract as Ferrari team principal
-
French cities impose curfews for teens to curb crime
-
Seals sing 'otherworldly' songs structured like nursery rhymes
-
India captain Gill run out in sight of Gavaskar record
-
Trump's global trade policy faces test, hours from tariff deadline
-
Study reveals potato's secret tomato heritage
-
Wirtz said I would 'enjoy' Bayern move, says Diaz
-
West Ham's Paqueta cleared of betting charges
-
Authorities abandon recovery of German Olympian killed in Pakistan
-
Talks over France, Lions game 'progressing': Benazzi
-
Magic Marchand adds gold to world record as McIntosh wins again
-
Sweden jihadist jailed for life over Jordan pilot burned alive
-
Zelensky signs bill ensuring anti-graft agencies' 'independence'
-
Sleepless in Singapore: Marchand wins gold, day after world record
-
England make early double strike in India series decider
-
Popovici wins 100m freestyle world gold for sprint double
-
Marchand wins 200m medley gold, day after world record
-
Thousands of Afghans scramble for chance to work in Qatar
-
Trump's envoy arrives in Israel as Gaza criticism mounts
-
McIntosh powers to third gold of worlds, 12-year-old Yu fourth
-
Hong Kong sees 3.1% growth in second quarter
-
Stocks, dollar mixed tracking Fed, tariffs, results
-
World Athletics brings in gene tests for female category eligibility
-
Trump says tariffs are making US 'great & rich' again
-
Pakistan opposition leader given 10 years for Imran Khan protests
-
India's Bumrah out of Oval finale as England bowl in fifth Test
-
Rights groups urge Nepal to reverse Telegram ban
-
BMW says can weather tariff storm despite profit plunge
-
Zelensky urges allies to push for 'regime change' in Russia
-
Renault profits slump as competition intensifies
-
Macau ex-lawmaker arrested in city's first national security law action
-
Beijing officials admit 'gaps' in readiness after rain kill dozens
-
Japan lifts tsunami advisory after Russia quake
-
Shell net profit retreats on lower energy prices
-
Unilever profit slides ahead of ice cream demerger
-
Trump announces new tariffs as deadline nears
-
US tariffs corrode steelmaker ArcelorMittal's profitability
-
BMW profits slump on China woes, US tariffs
-
Russia strikes kill six in Kyiv, Moscow says captured key town
-
Firms in Vietnam walk tightrope as Trump's transshipping rule looms
-
China summons chip giant Nvidia over alleged security risks
-
Veteran White gets fairytale sendoff for 'deflated' Wallabies
-
Trump gets his way on tariffs, but global trade system intact for now
-
Myanmar junta ends state of emergency in election run-up
-
Lions make two changes for final Wallabies Test
RIO | 0.7% | 59.91 | $ | |
CMSC | -0.05% | 22.589 | $ | |
SCU | 0% | 12.72 | $ | |
BCC | -1.26% | 83.83 | $ | |
BCE | -0.32% | 23.454 | $ | |
CMSD | 0.17% | 23.1 | $ | |
JRI | 0.04% | 13.115 | $ | |
NGG | 0.52% | 70.558 | $ | |
RYCEF | 7.55% | 14.17 | $ | |
BTI | 1.78% | 54.121 | $ | |
GSK | -2.19% | 38.135 | $ | |
VOD | -2.17% | 10.825 | $ | |
BP | -0.06% | 32.23 | $ | |
AZN | -1.89% | 75.17 | $ | |
RELX | 0.52% | 52.05 | $ | |
RBGPF | 0.52% | 74.42 | $ | |
SCS | -0.49% | 10.28 | $ |

US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
K.Sutter--VB